Severe malaria's hidden toll: new study probes lasting damage in adults
NCT ID NCT06992297
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study from a French hospital looked at long-term after-effects in 56 adults who had severe malaria. Researchers used a questionnaire to check for physical, thinking, and emotional problems one year after diagnosis. The goal is to better understand and track these lasting issues to improve follow-up care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict and manage long-term complications after severe malaria in adults.
- What could go wrong
- This is a small, single-center observational study with only 56 participants, so findings may not apply to all patients or regions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
56 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female over 18 years of age * Have been diagnosed with severe malaria according to WHO criteria and have been treated between 1/1/2018 and 321/12/2024 at the AP-HM * Have been treated with Artesunate IV (MALACEF®) (at least one dose) * Patient who has received information about the study and has not expressed opposition * Patient benefiting or entitled to benefit from a social security scheme Exclusion Criteria: * Patients with advanced neurodegenerative pathology pre-existing the malaria attack * Subjects covered by articles L1121-5 to 1121-8 of the Public Health Code (minor patients, patients of legal age under guardianship, curatorship or safeguard of justice, patients deprived of their liberty, pregnant or breast-feeding women), * Persons who do not understand French
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Falciparum; malaria are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique Hopitaux de Marseille
Marseille, 13354, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.